MedPath

VICOR Study-High Frequency Chest Wall Oscillations (HFCWO) in Patients With Acute Respiratory Failure and Hypersecretion

Not Applicable
Recruiting
Conditions
Acute-on-chronic Respiratory Failure
Airway Clearance Impairment
Acute Respiratory Failure
Interventions
Device: High Frequency Chest Wall Oscillations via The Vest® Airway Clearance System
Registration Number
NCT05751707
Lead Sponsor
Raffaele Scala
Brief Summary

The study aims to evaluates if the treatment with HFCWO Via The Vest® Airway Clearance System, in addition to standard care in critically ill patients admitted in the Respiratory Intensive Care Unit for acute respiratory failure or acute on chronic respiratory failure and unable to manage secretions, could primarily prevent the need for bronchoscopy, and secondarily shorten duration of non invasive respiratory therapy, shorten length of stay and reduce mortality.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
88
Inclusion Criteria
  • Diagnosis of acute respiratory failure (ARF) or acute on chronic respiratory failure (including patients having home oxygen therapy, HFNC, NIV) both hypercapnic ARF (PaCO2 > 45 mmHg; PaO2/FiO2 <300) or hypoxaemic (PaCO2 <45 mmHg; PaO2/FiO2 <300);
  • Informed consent from patient or legal tutor;
  • Accessory respiratory muscles use;
  • Respiratory rate above 25 apm;
  • Use of non invasive respiratory therapy (NIRT) NIV+/-HFNC or HFNC alone since RICU admission
  • Kelly neurological index ≤ 3
  • Excessive airway mucus secretion (clinical evaluation asking the patient to cough) and inability to efficiently remove secretions (evaluated with the Cough Peak Flow (CPF) measurement. A CPF under 270 Lpm is highly suggestive of inadequate cough which prevent the patient from adequately manage and remove airway secretions.
  • Cough score < 3: in the case of inability to perform CPF measurement due to poor patient collaboration, cough adequacy will be evaluated by a respiratory physiotherapy with a semiquantitative score ("Cough score") based on the measurement of sputum volume produced after coughing three times (1 point: less than 2 mL, 2 points: 2-6 mL, 3 points: more than 6 mL).
Exclusion Criteria
  • Patient unwillingness or incapability to provide informed consent
  • Need for subcontinuous NIV(more than 20 hours per day)
  • Kelly neurological index >3
  • Cardiac arrest
  • Severe haemodynamic instability (more than two amines required);
  • acute coronary syndrome;
  • Psychomotor agitation unresponsive to analgo-sedation (RASS> 1)
  • Contraindications to HFCWO use: acute pneumothorax (even if chest drainage is not required ); severe chest wall deformities (pectus excavatum, pectus carinatum or pectus arcuatum); severe obesity (BMI >40 kg/m2); pregnancy; thoracic or abdominal surgery in the six previous weeks
  • Nasal swab positivity to Sars-CoV-2
  • Need for endotracheal intubation or urgent bronchoscopy for excessive airway mucus

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
HFNC & HFCWOHigh Frequency Chest Wall Oscillations via The Vest® Airway Clearance SystemPatient with acute or acute on chronic respiratory failure is treated with high flow nasal cannulae oxygen AND High Frequency Chest Wall Oscillations
NIV+/-HFNC (non invasive ventilation +/- high flow nasal cannulae) & HFCWOHigh Frequency Chest Wall Oscillations via The Vest® Airway Clearance SystemPatient with acute or acute on chronic respiratory failure is treated with non invasive ventilation (with or without high flow nasal cannulae oxygen) AND High Frequency Chest Wall Oscillations
Primary Outcome Measures
NameTimeMethod
Rate of patients undergoing bronchoscopyFrom date of randomization until the date when the patients undergoes bronchoscopy becauase he/she is unable to spontaneously remove secretion assessed as worsening of gas exchange or of radiological appearance, whichever comes first, up to 30 days

Bronchoscopy is required when the patient is unable to spontaneously remove secretions despite physiokinesitherapy (Cough score \< 3 and gas exchange deterioration during NIRT (PaO2/FiO2\<200 or PaO2 \<60 and/or PaCO2 increasement of 20%) and/or radiological worsening (development of lobar/multilobar/pulmonary atelectasis or pre-existing atelectasis worsening)

Secondary Outcome Measures
NameTimeMethod
Number of patients who undergo endotracheal intubation for inability to manage secretions in patients without a "do not resuscitate" (DNR) indication and RICU mortality for DNR patientsFrom date of randomization until the date when the patient intubated for acute worsening of clinical conditions, assessed during hospital stay, up to 90 days
Days of non-invasive respiratory treatment (NIRT) durationFrom date of randomization until the date when the patient no more requires NIRT because of improving gas exchange, assessed up to 30 days (days)

Evaluates if reduction of NIRT duration in patients treated with HFCWO compared to patients treat only with NIRT, occurs

Days of RICU (respiratory intensive care unit) stayFrom date of randomization until the date when the patient is clinically stable to be discharged from RICU, assessed up to 30 days (days-weeks)

Evaluates if reduction of duration of RICU stay in patients treated with HFCWO compared to patients treat only with NIRT, occurs

Sputum volume10 days
Comfort in using The Vest airway clearance system in patients treated with HFCWO + NIRT48 hours after HFCWO treatment starting

Likert questionnaire scale will be used to assess this outcome

Respiratory function tests 90 days after hospital discharge90 days after hospital discharge
Number of patients who undergo endotracheal intubation and Invasive mechanical ventilationFrom date of randomization until the date when the patient intubated for acute worsening of clinical conditions, assessed during hospital stay, up to 90 days

Evaluates if reduction of need for Invasive mechanical ventilation in patients treated with HFCWO compared to patients treat only with NIRT, occurs

Trial Locations

Locations (1)

Ospedale San Donato

🇮🇹

Arezzo, AR, Italy

© Copyright 2025. All Rights Reserved by MedPath